Prenatal Carbamazepine Exposure and Academic Performance in Adolescents

Background and Objectives To investigate whether children born to mothers who used carbamazepine during pregnancy had worse academic performance in adolescence. Methods This population-based cohort study included all live-born singletons in Denmark between 1996 and 2002 who participated in the national ninth-grade exit examination (n = 370,859). Those born to mothers with prescription of antiseizure medications other than carbamazepine during pregnancy were excluded. We examined the association of in utero exposure to maternal carbamazepine redeemed during pregnancy (n = 290) with academic performance of offspring, defined by the scores in Danish and mathematics in ninth-grade exit examination. We estimated mean z-score difference with linear regression adjusted for socioeconomic factors and potential indications, including epilepsy and medication for other psychiatric disorders. Additional analyses addressing confounding by indication included comparison between in utero exposed vs past exposed and between past exposed and never exposed. In utero exposure to valproate monotherapy was used as a positive control and in utero exposure to lamotrigine as a negative control. Results At the age of 16.1 (SD 0.4) years, adolescents in utero exposed to maternal carbamazepine monotherapy had lower scores both in Danish and mathematics in ninth-grade exit examination (adjusted z-score difference, −0.14 [95% CI −0.24 to −0.05] and −0.17 [95% CI −0.28 to −0.07], respectively). In utero exposure to carbamazepine monotherapy was associated with lower scores than past exposure only (adjusted z-score difference, −0.24 [95% CI −0.41 to −0.06] for Danish and −0.25 [95% CI −0.44 to −0.06] for mathematics), while past exposure to carbamazepine was associated with minor decrease in offspring's academic performance (adjusted z-score difference, −0.02 [95% CI −0.09 to 0.06] for Danish and −0.07 [95% CI −0.16 to 0.01] for mathematics). The association was also observed for in utero exposure to valproate monotherapy, but not for in utero exposure to lamotrigine. Discussion In utero exposure to carbamazepine was associated with poorer academic performance in adolescence, as represented by lower scores in ninth-grade exit examination in Danish and mathematics. Additional studies are needed to confirm these findings because of limitations in this study and variable findings in prior studies. Classification of Evidence This study provides Class III evidence that academic performance, as reflected in ninth-grade exit examinations in Danish and mathematics, was worse among those exposed to carbamazepine monotherapy in utero, compared with those without in utero exposure to antiseizure medications.

[1]  J. Leach,et al.  Delivery of care, seizure control and medication adherence in women with epilepsy during pregnancy , 2022, Seizure.

[2]  M. Gissler,et al.  Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability. , 2022, JAMA neurology.

[3]  D. Schomer,et al.  Neuropsychological effects in children exposed to anticonvulsant monotherapy during gestation: Phenobarbital, carbamazepine, and phenytoin , 2022, Epilepsy & Behavior.

[4]  K. Meador,et al.  Antiseizure Medication Concentrations During Pregnancy: Results From the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) Study. , 2022, JAMA neurology.

[5]  J. Christensen,et al.  Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs With Intellectual Disability and Delayed Childhood Milestones , 2020, JAMA network open.

[6]  F. Ramus,et al.  Risk of early neurodevelopmental outcomes associated with prenatal exposure to the antiepileptic drugs most commonly used during pregnancy: a French nationwide population-based cohort study , 2020, BMJ Open.

[7]  K. Meador,et al.  Effects of periconceptional folate on cognition in children of women with epilepsy , 2019, Neurology.

[8]  M. Bjørk,et al.  Language impairment in children aged 5 and 8 years after antiepileptic drug exposure in utero – the Norwegian Mother and Child Cohort Study , 2019, European journal of neurology.

[9]  Sigrun Alba Johannesdottir Schmidt,et al.  The Danish health care system and epidemiological research: from health care contacts to database records , 2019, Clinical epidemiology.

[10]  D. Thurman,et al.  Antiepileptic Drug Treatment Patterns in Women of Childbearing Age With Epilepsy. , 2019, JAMA neurology.

[11]  M. Schumacher,et al.  HLA‐B*57:01 confers genetic susceptibility to carbamazepine‐induced SJS/TEN in Europeans , 2019, Allergy.

[12]  M. Daly,et al.  Immunity and mental illness: findings from a Danish population-based immunogenetic study of seven psychiatric and neurodevelopmental disorders , 2019, European Journal of Human Genetics.

[13]  S. Vollset,et al.  Association Between Maternal Folic Acid Supplementation and Congenital Heart Defects in Offspring in Birth Cohorts From Denmark and Norway , 2019, Journal of the American Heart Association.

[14]  K. Meador,et al.  Fetal antiepileptic drug exposure and learning and memory functioning at 6 years of age: The NEAD prospective observational study , 2019, Epilepsy & Behavior.

[15]  C. Lintas,et al.  Linking genetics to epigenetics: The role of folate and folate‐related pathways in neurodevelopmental disorders , 2018, Clinical genetics.

[16]  C. Torp-Pedersen,et al.  In utero exposure to antiepileptic drugs is associated with learning disabilities among offspring , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[17]  T. Laursen,et al.  Association Between Prenatal Valproate Exposure and Performance on Standardized Language and Mathematics Tests in School-aged Children , 2018, JAMA neurology.

[18]  Lippincott Williams Wilkins,et al.  Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies , 2017, Neurology.

[19]  N. Malek,et al.  A review of medication adherence in people with epilepsy , 2017, Acta neurologica Scandinavica.

[20]  R. Ahmed,et al.  Maternal carbamazepine alters fetal neuroendocrine-cytokines axis. , 2017, Toxicology.

[21]  A. Milstein,et al.  Association Between the Birth of an Infant With Major Congenital Anomalies and Subsequent Risk of Mortality in Their Mothers. , 2016, JAMA.

[22]  P. Pennell Use of Antiepileptic Drugs During Pregnancy: Evolving Concepts , 2016, Neurotherapeutics.

[23]  L. Jong‐van den Berg,et al.  Antiepileptic drug prescribing before, during and after pregnancy: a study in seven European regions , 2015, Pharmacoepidemiology and drug safety.

[24]  B. Bytoft,et al.  Academic Achievement in Primary School in Offspring Born to Mothers With Type 1 Diabetes (the EPICOM Study): A Register-Based Prospective Cohort Study , 2015, Diabetes Care.

[25]  A. H. Friberg,et al.  Few Danish pregnant women follow guidelines on periconceptional use of folic acid. , 2015, Danish medical journal.

[26]  K. Meador,et al.  IQ at 6 years after in utero exposure to antiepileptic drugs , 2015, Neurology.

[27]  A. Marson,et al.  Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. , 2014, The Cochrane database of systematic reviews.

[28]  Henrik Toft Sørensen,et al.  The Danish Civil Registration System as a tool in epidemiology , 2014, European Journal of Epidemiology.

[29]  V. Smith,et al.  Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism , 2014, Archives of Disease in Childhood: Education & Practice Edition.

[30]  C. Lavebratt,et al.  Prenatal Exposure to Carbamazepine Reduces Hippocampal and Cortical Neuronal Cell Population in New-Born and Young Mice without Detectable Effects on Learning And Memory , 2013, PloS one.

[31]  Mogens Vestergaard,et al.  Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. , 2013, JAMA.

[32]  K. Meador,et al.  Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study , 2013, The Lancet Neurology.

[33]  M. Werler,et al.  Use of antiepileptic medications in pregnancy in relation to risks of birth defects. , 2011, Annals of epidemiology.

[34]  K. Meador,et al.  Relationship of child IQ to parental IQ and education in children with fetal antiepileptic drug exposure , 2011, Epilepsy & Behavior.

[35]  J. Morrow,et al.  Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine , 2011, Archives of Disease in Childhood.

[36]  K. Meador,et al.  Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. , 2011, Brain : a journal of neurology.

[37]  M. Loane,et al.  Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study , 2010, BMJ : British Medical Journal.

[38]  B. Källén,et al.  School performance at age 16 in children exposed to antiepileptic drugs in utero—A population‐based study , 2010, Epilepsia.

[39]  Gerhard A Zielhuis,et al.  Teratogenic mechanisms of medical drugs. , 2010, Human reproduction update.

[40]  K. Meador,et al.  Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. , 2009, The New England journal of medicine.

[41]  V. K. Knudsen,et al.  Folic Acid for the Prevention of Neural Tube Defects: The Danish Experience , 2008, Food and nutrition bulletin.

[42]  Per Sidenius,et al.  Incidence and prevalence of epilepsy in Denmark , 2007, Epilepsy Research.

[43]  J. Olsen,et al.  Validation of epilepsy diagnoses in the Danish National Hospital Register , 2007, Epilepsy Research.

[44]  V. Hiilesmaa,et al.  Normal intelligence in children with prenatal exposure to carbamazepine , 2004, Neurology.

[45]  L. Cooper Delivery of care. , 2002, Nephrology news & issues.

[46]  L. de Jong-van den Berg,et al.  Do Pregnant Women Report Use of Dispensed Medications? , 2001, Epidemiology.

[47]  P. Lindsay Epilepsy in pregnancy. , 1990, Nursing times.

[48]  T. Einarson,et al.  Long-Term Developmental Outcome of Children of Women with Epilepsy, Unexposed or Exposed Prenatally to Antiepileptic Drugs , 2010, Drug safety.